MEA Atherectomy Devices Market

North America Atherectomy Devices Market Size (2023 to 2028)

The Middle East and Africa atherectomy devices market is expected to grow from USD 44 million in 2023 to USD 59.5 million by 2028, growing at a CAGR of 6.22% from 2023 to 2028.

Atherectomy is a surgical procedure to remove atherosclerotic plaque from diseased arteries without affecting the rest of the vessel wall. Atherectomy devices are utilized productively in treating coronary heart disease and peripheral arterial disease. Atherosclerotic plaques are placed in the coronary or peripheral arterial vasculature and have unique characteristics depending on the plaque's texture. Depending on their characteristics, these devices are designed differently for cutting, shaping, sanding, or spraying plates. The Middle East holds the smallest share of the global atherectomy devices market due to the presence of economically diverse countries and the reduced number of initiatives taken by the government.

The increasing demand for coronary and vascular interventions due to increased peripheral artery disease (PAD) and coronary heart disease (CAD) in recent years is expected to drive the market for MEA atherectomy devices shortly. In addition, diabetes, critical limb ischemia, and cardiovascular disease have recently increased, even among the youngest patients. It is estimated that the increasing incidence of vascular diseases and disorders related to or caused by calcified peripheral and coronary arteries, reduced blood flow, and amputation of the lower limbs will lead to the demand for atherectomy devices between 2020 to 2025.

Simultaneously, it is expected to increase sustainably over the next few years. Several clinical trials to demonstrate the device's effectiveness also contribute to the high demand. Trials such as DEFINITIVE LE (determining the Silver Hawk Peripheral Plaque Removal System's effectiveness for treating infrainguinal vessels / lower limbs) and EASE (Endovascular Atherectomy Safety and Effectiveness) have shown a higher success rate. 90%, which guarantees the efficiency of the devices in question. These factors and MBA's presence of medical devices in developed and emerging markets drive the demand for directional atherectomy devices.

Factors such as postoperative complications and a lack of qualified medical professionals limit the market's growth.

This research report on the MEA Atherectomy Devices Market has been segmented and sub-segmented into the following categories:

By Type: 

• Directional
• Rotational
• Orbital
• Lateral

By Application: 

• Peripheral
• Cardiovascular
• Neurovascular

By End User: 

• Hospitals
• Surgical Centers
• Research Laboratories
• Academic Institutes

By Country:  

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe

The hospital segment is expected to dominate the market during the forecast period due to its advanced infrastructure and ease of access to treatments unavailable in outpatient surgery centers. The development of the MEA atherectomy devices market can be accredited to the rising need for minimally invasive surgical procedures and increasing research activity in atherectomy worldwide. Additionally, increasing healthcare expenditure and the prevalence of Peripheral Arterial Disease (PAD) will likely add new opportunities to the MEA Atherectomy Devices market during the forecast period.

UAE is expected to grow with a CAGR of 7.3% during the forecast period. The growth of this country is due to factors like increasing obesity and a large number of people who recover from atherosclerosis and cancer, which has increased importantly over the period. In addition, the growing obtainment of minimally invasive procedures for atherectomy will raise the stipulation for these devices worldwide, increasing the growth of the atherectomy devices market in the MEA.

KEY MARKET PLAYERS:

Some of the prominent companies leading in the MEA Atherectomy Devices Market profiled in the report are Bayer HealthCare, C. R. Bard, Inc., Cardinal Health (Cordis), Avinger, Inc., Boston Scientific Corporation, Straub Medical AG, St. Jude Medical, Cardiovascular Systems, Inc., and Spectranetics.